S1PR1 and psoriasis: In addition, 50% of psoriasis patients treated with the selective S1P1/3/5 modulator, ponesimod exhibited a 75% improvement in Psoriasis Severity Index (PASI) at week 16, whereas only 13.4% of the placebo group improved [97].